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Table 1: Findings of seroprevalence studies investigating presence of ebolavirus immunoglobulin G antibodies in ‘asymptomatic’ populations, 1961 - 2016 
 
A = populations with household contact or known case contact    
B = populations without known contact but in outbreak areas or villages with cases   
C = general population – no known outbreak exposure or contact   
 
Location 
Year sera 
collected 
Population type (as described in 
paper) 
Group 
No. of 
samples 
# IgG +ve 
Species 
     % +ve   
Assay 
type  
Cut-off (as 
described in 
paper 
Antigen & validation information Notes 
Assab, Awash, Blue 
Nile, Illubor, & Ogaden 
regions, Ethiopia1 
1961/62    
Asymptomatic individuals from area 
not affected by ongoing Yellow Fever 
epidemic  
C 178 42 
EBOV 
24%  
IFA(w)  ≥1:16 
Antigens: Polyvalent ELM (Ebola-Lassa-
Marburg viruses) & monovalent EBOV 
(Mayinga): all sera reacting with ELM also 
reacted with monovalent EBOV antigen but 
not with monovalent Marburg and Lassa. 
Samples from symptomatic Yellow 
Fever-negative individuals also tested: 
12% positive. 
N.W. Zaire (now 
Democratic Republic 
of Congo DRC)2 
1972-78 
General population from area west of 
Yambuku (site of 1st recorded 
outbreak in 1976) 
C 251 
 
43 
 
26 
EBOV 
17.1%  
 
10.4%  
IFA(w) 
 
≥1:16 
 
≥1:64 
Antigen: EBOV (May. 80826)  
Harbel, Bong town, 
Yekepa, Liberia3 
1973 
Staff & family members of rubber and 
mining companies  
C 592 83 
Ebolavirus 
14.0% 
ELISA/ 
WB 
Not stated Antigen not stated 
Sera taken in 1973 and investigated 
for Lassa and ebolavirus in ~1986. 
Ebola statistic reported without 
further information.  
Northern Rhodesia 
(now Zimbabwe)4 
1975 “Control group” C 243 
 
2 
 
0 
EBOV 
0.8%  
 
0.0%  
IFA(w) 
 
≥1:8 
 
≥1:64 
Antigen not specified in report: Kuhn52 notes 
antigen as EBOV 
Areas sampled had no known 
outbreak 
Yambuku, Zaire (DRC)5 1976 
Asymptomatic contacts of cases A 404 10 
EBOV 
2.5%  
IFA(w) ≥1:64 
Antigen: EBOV 
 
Validation: Repeat testing of the 4 antibody 
positive with no known contact gave the same 
results. 32/33 (97%) positive samples 
(including samples from cases) confirmed 
positive by CDC (US)4 (p141)           
 Residents from villages with cases but 
no known contact 
B 448 4 
 
EBOV 
0.9 
Residents from 4 neighbouring 
villages with no cases 
C 442 5 
EBOV 
1.1%  
Maridi, Sudan (now 
South Sudan)6 
 
1976 
Close family contacts  
 
A 
 
93 
 
13 
SUDV 
14.0%  
IFA(w) ≥1:8 
Antigen: SUDV 
 
Validation: 42 of 48 clinically diagnosed 
survivors from Nzara (87%) were considered 
positive using the same IFA protocol. Several 
samples from Nzara were retested and 
confirmed positive by CDC (US) using the same 
protocol.   
9 antibody positive family contacts 
had symptoms and have been 
excluded from these figures. Not clear 
if all subjects in this group were 
interviewed about symptoms. 
Asymptomatic Maridi schoolboys with 
no known contact 
 
B 
 
29 
 
3 
SUDV 
10.3% 
 
Asymptomatic hospital staff with 
probable/possible contact 
 
A 
 
64 
 
7 
SUDV 
10.9% 
4 nurses; 1 cleaner, 1 toilet cleaner, 1 
water carrier were positive 
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Nzara, Sudan (now 
South Sudan)6 
1976 
Asymptomatic cotton factory workers 
(site of index case but reportedly no 
direct contact) 
B 109 
 
7 
SUDV 
6.4%  
IFA(w) ≥1:8  
Among factory workers titre range 
was 1:16 - 1:32 
Close family contacts of clinically 
diagnosed cases 
A 78 1 
SUDV 
1.3% 
Only 6/31 (19.4%) of clinically 
diagnosed subjects were antibody 
positive, and none had levels > 1:32 
San Blas Islands, 
Panama4 
1977 San Blas Indians C 200 1 
EBOV 
0.5% 
 
IFA(w) ≥1:64 
Antigen: not specified in report: Kuhn52 records 
antigen as EBOV 
Areas sampled had no known 
outbreak. Method of selection not 
known 
Tandala, Zaire (DRC)7 1977-78 
Missionaries and ‘a few’ hospital staff 
with case contact (1977) 
A 50 0 
EBOV 
0% 
IFA(w) ≥1:16 Antigen: EBOV  
One doctor, who tested positive in 
1977 and 1978 and had history of 
severe illness after attending the 
autopsy of a haemorrhagic fever 
victim in 1972, is excluded. Some 
individuals gave samples in both the 
1977 and 1978 groups 
Hospital staff with case contact (1978) A 71 0 
EBOV 
0% 
Residents of villages with confirmed 
/suspect cases 
B 346 21 
EBOV 
6.1% 
Residents of other villages in same 
area 
B 750 58 
EBOV 
7.7%  
Liberia 8 1978-79 
Random rural general population in 
multiple counties 
C 433 26 
Ebolavirus 
6.0%  
IFA(w) ≥1:16 
 
Antigens: unspecified ebolavirus, Marburg & 
Lassa viruses. No sera positive for ebolavirus 
was positive for MARV or LASV. 
 
No known outbreak. Titre range: 1:16 
to 1:1024 
Nzara/Yambio, (South) 
Sudan9 1979 
Asymptomatic adult family members 
of cases  with known physical contact 
A 38 12 
Ebolavirus 
32% 
IFA(w) ≥1:16 Antigen: unspecified 
 
Asymptomatic adult family members 
of cases who denied physical contact 
B 23 3 
Ebolavirus 
13% 
 
 
 
Adults from families without known 
cases in same area  
B 45 8 
Ebolavirus 
18% 
Unknown if these people were 
exposed in 1976 outbreak, which 
could explain the high prevalence  
Bangassou, Central 
African Republic 
(CAR)10 
1979 
General population in forest and 
semi-forest zones 
C 499 
 
10 
 
3 
Ebolavirus 
2.0% 
 
0.6% 
IFA(w) 
 
≥1:16 
 
≥1:64 
 
Antigen: Polyvalent of unspecified ebolavirus, 
MARV & LASV, followed by monovalent test 
for positive samples. Positive sera sent to CDC 
(US) for repeat testing; results not reported. 
 
Areas sampled had no known 
outbreak 
Moloundou, Lolodorf 
Bipindi, Lomie, 
Yaounde & Pete, 
Cameroon11 
1980 
General population in five regions 
(forest, pre Sahelian savannah and 
the capital) and different ethnic 
groups 
C 1517 147 
Ebolavirus 
9.7%  
IFA(w) ≥1:16 
Antigens: unspecified ebolavirus provided by 
CDC (US)  
No known outbreak. Positives in all 
areas, range 3%-23%. Highest in 
Pygmies and rain forest farmers. 6% 
in the capital, Yaoundé. Report to 
OCEAC in the same year gave 
positivity of 6.2% (51/821) in 
Moloundou, compared to 13.2% for 
the same location in this study, and 
29% (20/70) in Mbatika, but positivity 
threshold used is not reported.63 
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Lugulu, western 
Kenya12 
1980 
Family and close neighbours of an IFA 
confirmed case (asymptomatic?) 
 
A 
 
84 
 
4 
Ebolavirus 
4.8% 
 
IFA (?) 
 
≥1:16 
Antigens: monospecific, triple (unspecified 
ebolavirus, MARV, LASV) and poly-antigen 
(CCHFV, RVFV, ebolavirus, LASV, MARV). 
 
Validation: sera examined at National Institute 
of Virology, Johannesburg and CDC(US): labs 
used different thresholds, so positive 
confirmed only where both found ≥1:16 
Area in Western Kenya, close to 
Nzoia. Samples collected during 
investigation of 2 MARV suspect cases 
who were later shown to be 
ebolavirus positive.  
Kenya13  
 
1980 
Different studies in 5 regions of 
Kenya:          - Lodwar, Laisamis, 
Masia, Malindi/Kilifi 
 
         - Nzoia 
C 
1058 
 
841 
18 
 
9 
EBOV/SUDV 
1.7% 
 
1.1% 
IFA(w) ≥ 1:16 
Antigens: inactivated unspecified ebolavirus, 
MARV, CCHFV, RVFV, & LASV; positives tested 
against EBOV(May) & SUDV (Boniface & 
Maleo). Authors report ‘most’ of the Nzoia 
samples were only tested against EBOV(May) 
No known outbreak but Nzoia cohort 
reported to include suspected cases 
and their contacts. Highest 
prevalence: Lodwar 7.8% (north-west 
Kenya). Note referenced paper 
includes some sera reported on in 
other papers.72 
Haute Ogooue, 
Gabon14 
1980 
General population in outbreak area 
but no known contact 
B 253 
 
16 
8 
 
 
5 
1 
 
 
21 
8 
EBOV 
6.3% 
3.2% 
 
SUDV 
2.0% 
0.4% 
 
EBOV/SUDV 
8.3% 
3.1% 
IFA(w) 
 
≥ 1:16 
≥1:64 
 
 
≥ 1:16 
≥ 1:64 
 
 
≥ 1:16 
≥1:64 
Antigens: inactivated polyvalent unspecified 
ebolavirus/LASV MARV: positives tested 
against EBOV(802850) & SUDV(802681). 
Samples from the Occupational 
Health Services, plus 28 women & 
their newborns.  One sample was 
positive ≥1:64 on both EBOV & SUDV 
Northern Rhodesia 
(now Zimbabwe)15 
1980  
Asymptomatic schoolboys (8-10y): no 
known outbreak  
C 486 
9 
 
4 
 
EBOV 
1.9% 
 
0.8% 
 
IFA(g) 
≥ 1:8 
 
≥ 1:128 
 
Antigen: polyvalent CCHFV, RVFV, LASV, 
MARV, unspecified ebolavirus slides provided 
by CDC (US): positives tested against individual 
antigens (EBOV & SUDV) 
 
Validation: 4 of 5 positive samples sent to CDC 
(US) were ≥1:128 in repeat IFA testing.  
None were positive for SUDV. 
 
Pool, Congo-
Brazzaville (now 
Republic of Congo)16 
1981 
Children from 20 villages aged 3-15 
years and unvaccinated for smallpox 
C 790 119 
Ebolavirus 
15.0% 
IFA(?) Not stated 
Antigen: polyvalent CCHFV, RVFV, LASV, 
MARV, unspecified ebolavirus; also tested  
against monovalent antigens 
Pool region is on the border with DRC. 
Areas sampled had no known 
outbreak but populations were 
selected for close contact with 
animals 
Grand Bassa, Liberia17 1981-82 
Individuals asymptomatic for EVD 
consisting of 106 epilepsy patients; 87 
healthy relatives of these patients; 32 
unrelated geographically matched 
controls.  
C 225 
26 
 
 
4 
 
 
29 
EBOV 
11.6% 
 
SUDV 
1.8% 
 
Overall 
12.9% 
IFA(w) unclear 
Antigen: polyvalent CCHFV, RVFV, LASV, 
MARV, EBOV (May), SUDV(Bon) (known as 
CRE2LM); positives retested against individual 
antigens. 
 
Validation: Difficulties with non-specific 
binding led researchers to replicate and use 
blinded observers to read results. Only 
samples with unequivocally positive results by 
2 observers were considered positive. 
No known outbreak. Similar 
proportion positive in each 
participant group. 38% epilepsy 
patients had a febrile illness 1-4 
weeks before onset of epilepsy, but 
no significant difference in 
seroprevalence with & without febrile 
history. Paper says 30 positives in 
total but one counted twice (positive 
for EBOV and SUDV). Titres ranged 
from 32-128 for EBOV; 6/29 had 
antibodies to more than 1 virus.  
4 
 
Sud-Ubangi sub-
region, DRC (includes 
Tandala)18 
1981-85 
Age/sex matched controls from the 
same villages as reported cases 
C 137 2 
Ebolavirus 
1.5% 
IFA(w) ≥1:64 
Antigen: polyvalent CRE2LM; positives tested 
against unspecified ebolavirus-specific 
antigens. 
 
In addition 188 contacts of possible 
and probable cases were tested; 28 
were positive at ≥1:64 but all had had 
symptoms fitting the definition of a 
possible or clinical case. It is not clear 
how many of the other contacts had 
symptoms. 
 
Northeastern, 
southeastern & 
western Gabon19 
1981-
1997 
Six rural communities (Makokou, 
Doussala, Doussieousou, Matadi-
Ngoussa, Moukoro, Latoursville):  sera 
gathered during onchocerciasis 
research  
C 1147 14 
 
 
 
EBOV 
1.2% ELISA (k) 
Mean +3 SD of 
OD of negative 
controls 
Antigen: EBOV 
 
Validation: In 2003, 6 of original 14 positives 
were re-bled (others unavailable): 2 were still 
positive. 14 controls (relatives and ‘cohorts’) 
were unreactive 
6 seropositives were from north-
eastern Gabon where outbreaks had 
occurred; 8 were from western 
communities more than 500km from 
known epidemics. Authors also 
investigate and correlate animal with 
human outbreaks. Conclude that less 
virulent strains of EBOV affected 
western areas. 
Madina-Ula, Guinea20 1982-83 
Healthy adults sampled during an 
outbreak of an unknown disease 
C 138 
 
11 
 
4 
 
 
2 
EBOV 
7.8% 
 
2.9% 
 
 
2.2% 
 
ELISA(r) 
 
ELISA(r) 
IFA(b) 
 
ELISA(r) 
IFA (b) 
 
≥ 1:8 
 
≥ 1:512 
≥ 1:16 
 
≥ 1:512 
≥ 1:64 
Antigen: EBOV 
Areas sampled had no known 
outbreak  
Benin21 1983 
General population, non-outbreak 
country 
C 603 2 
EBOV or 
SUDV? 
0.3% 
IFA (?) ≥ 1:64 Antigen: EBOV, SUDV 
Unpublished data cited by Gonzalez et 
al (2005): no further information, not 
specified which ebolavirus antigen 
samples were reactive to. 
Ethiopia, Awash valley1 1983 Unexposed children C 250 0 
EBOV 
0.0% 
IFA(w) ≥ 1:16 
 
Antigens: Polyvalent ELM (Ebola-Lassa-
Marburg viruses) & monovalent EBOV (May) 
 
Areas sampled had no known 
outbreak 
 
Karamoja, Uganda22  1984 
‘Healthy’ adults 20-40y recruited 
during visits to a health centre, 
excluding any with current or recent 
fever 
C 132 
 
4 
 
 
4 
 
EBOV 
3.0% 
 
SUDV 
3.0% 
IFA(w) unclear 
Antigen: polyvalent CCHFV, RVFV, LASV, 
MARV, EBOV (May), SUDV(Bon) (CRE2LM); 
positives retested against individual antigens. 
No known outbreak. Not clear if some 
samples had antibodies to both EBOV 
& SUDV. Not specified how many > 
1:64. All samples < 1: 128.  
Mobai, Sierra Leone & 
unspecified location 
Sudan23 
<1984 
No information on population type: 
general population assumed from 
description 
 
       -  Mobai, Sierra Leone 
 
 
       -  Sudan 
C 
 
 
 
556 
 
 
284 
 
 
 
10 
10 
 
1 
0 
 
 
EBOV 
(a) 1.8% 
(b) 1.8% 
 
(a) 0.35 
(b) 0 
 
 
(a) ELISA 
+ve/IFA+
ve 
 
(b) ELISA 
+ve/ IFA -
ve or 
unclear  
ELISA: +ve 
within 2 SD of 
+ve ref. sera;     
-ve within 1 SD 
of negative ref 
sera 
 
IFA ≥ 1:100 
Antigen: EBOV 
 
Validation: All? samples were tested using 
both assays 
Year of sample collection is not 
recorded. Paper reports a high level 
of cross reactivity with MARV, lasting 
a number a number of years after 
infection. 
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Haute Ogooue, 
Gabon24  
1985 Inhabitants of Ambinda village C 213 
 
20 
6 
 
 
2 
1 
 
 
22 
7 
EBOV 
9.4 % 
1.4% 
 
SUDV 
0.9 % 
0.5% 
 
Overall 
10.3% 
3.3% 
IFA (j) 
 
≥ 1:16 
≥ 1:64 
 
 
≥ 1:16 
≥ 1:64 
 
 
≥ 1:16 
≥ 1:64 
Antigen: polyvalent CCHFV (IB-AR-10200 
Nigeria), RVFV (ZH-501 Egypt), LASV (Josiah), 
MARV (Musoki), EBOV (May), SUDV(Bon) 
(CRE2LM); positives retested against individual 
antigens. 
No known outbreak 
 
Nola,Ikaumba, Bozo, 
Bangassou, Mbre & 
Birao, Central African 
Republic 25 
1984-85 
General population from 5 ecological 
regions including one close to 
Zaire/DRC outbreak area 
C 836 
152 
 
63 
EBOV 
18.2 % 
 
SUDV 
7.5 % 
IFA(j) 
 
≥ 1:16 
 
Antigens: EBOV (May), SUDV (Bon), MARV 
(Mus) 
No known outbreak but Zemio which 
borders DRC accounted for 43% of 
EBOV positives 
Nola,Ikaumba, Bozo, 
Bangassou, Mbre & 
Birao, Central African 
Republic 26 
1984-85 
Asymptomatic general population 
from 5 ecological distinct zones 
selected on accessibility: additional 
villages wer chosen where multiple 
ethnic groups coexisted. 
C 
4295* 
 
4078* 
 
681 
209 
 
 
853 
259 
 
 
914 
335 
EBOV 
15.9% 
5.1% 
 
SUDV 
19.8% 
6.4% 
 
Overall 
21.3% 
8.2% 
IFA (j) 
 
≥ 1:16 
≥ 1:128 
 
 
≥ 1:16 
≥ 1:128 
 
 
≥ 1:16 
≥ 1:128 
Antigens: polyvalent EBOV (May), SUDV (Bon), 
MARV (Mus), LASV (Jos), CCHFV (10200), 
RVFV(ZH501); positives (≥ 1:16) retested 
against monovalent antigen.  
 
Validation: 185 samples were reanalysed by 
ELISA in 1996: results confirmed original 
analysis.21 
Study linked to one above in CAR25 
but using different set of sera 
sampled in the same period.  
* Two different denominators are 
cited: 4296 people are reported for all 
titre levels;  4078 people are reported 
in the table describing only samples 
showing titres ≥ 1:128. 
Highest prevalence in woods and 
forest regions. 86% of titres ≥ 1:64 but 
reached as high as 1:2048  
Nkongsamba, 
Cameroon27 
 1985 
Randomly selected urban general 
population (15-44 years) 
 
C 
 
375 
 
7 
5 
 
Ebolavirus 
1.9% 
1.3% 
 
IFA (?) 
 
 
≥ 1:16 
≥ 1:64 
 
Antigens: polyvalent unspecified ebolavirus, 
CCHRV, RVFV, MARV) 
These samples were included in the 
following multi-country study which 
used a different threshold.28  One 
sample was positive for both 
ebolavirus and RVFV 
Central Africa28 (now 
Middle Africa) 
 
 
 
 
1985-87 
Randomly selected sera collected in: 
Cameroon (Mora, Maroua, 
Nkongsamba) 
Central African Republic (Bangui) 
Chad (N’djamena) 
Republic of Congo (Pointe Noire, 
Brazzaville) 
Equatorial Guinea (Bioco Island, 
Nsork) 
Gabon (Libreville, Port-Gentil, 
Ogooue-Ivindo, Haut Ogooue, 
Ngounie) 
C 
 
1152 
327 
334 
728 
688 
1841 
 
89 
107 
334 
51 
111 
259 
EBOV/SUDV 
7.7% 
32.7% 
3.6% 
7.0% 
16.1% 
14.0% 
IFA (w) ≥ 1:16 
Antigens: polyvalent EBOV (May), SUDV (Bon), 
MARV (Mus), LASV (Jos), CCHFV (10200), 
RVFV(ZH501); positives (≥ 1:16) retested 
against monovalent antigen. 
 
Areas sampled had no known 
outbreak  
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Chobe, Northern 
Botswana29 
1984-86 
1984: 52 asymptomatic villagers) 
1985: 25 villagers with non-specific or 
ictero-haemorrhagic symptoms  
1986: 77 asymptomatic villagers  
 
C 
 
154 
 
0 
EBOV/SUDV 
0% 
 
IFA (J) 
 
≥ 1:16 
Antigens: polyvalent CCHFV, RVFV, LASV, 
MARV, EBOV (May), SUDV(Bon): positives re-
tested against monovalent antigens. 
Areas sampled had no known 
outbreak. Unable to separate results 
for the symptomatic group. Only 
reaction found was against RVFV. 
Testing performed in Paris. 
Lobaye, Central 
African Republic30 
1987 
Asymptomatic general population, 
Lobaye district: Pygmy hunter-gathers  
C 127 31 
EBOV/SUDV 
24.4% 
IFA (J) ≥ 1:128 
Antigens: polyvalent EBOV (May), SUDV (Bon), 
MARV (Mus), LASV (Jos), CCHFV (10200), 
RVFV(ZH501); positives (≥ 1:16) retested 
against monovalent antigen, considered 
reactive if ≥ 1:128. 
 
Validation: 296 samples from this study and 
185 samples from the CAR 1984-85 study 
above were re-analysed in 1996 using ELISA 
(≥1:400 & sum of 4 ODs ≥ 1.000). 6.2% were 
Ebola  IgG positive (30/481) compared to 6.4% 
in these samples previously by IFA.21,26 
Area with no known outbreak.  
 
Of the positives, 45 reacted to both 
EBOV & SUDV:  it is not possible to 
identify how this splits between the 
groups.  
Asymptomatic general population 
Lobaye district: Mozombo/Mbati 
subsistence farmers 
C 300 42 
EBOV/SUDV 
14.4% 
Nigeria31 
 
1988 
Asymptomatic general population in 
different locations  
C 1677 
 
30 
 
 
22 
SUDV  
1.8% 
 
EBOV/SUDV 
1.3% 
 
IFA(w) ≥ 1:10 
Antigens: polyvalent CCHFV, RVFV, LASV, 
MARV, EBOV (May), SUDV(Bon): positives with 
titre ≥ 1:10 retested against monovalent 
antigens. Known positive/negative controls 
used 
Areas sampled had no known 
outbreak. All positive samples came 
from savannah areas 
(Benue/Gongola) 
Of the positives, none reacted to 
EBOV alone. 
Antanarivo, Mandoto, 
andasibe, 
Tsiroanomandidy & 
Ampijoroa, 
Madagascar32 
1989 
Asymptomatic adults from 5 different 
areas (urban & rural, cattle-lands, 
forested) 
C 381 17 
EBOV 
4.5% 
IFA (j) ≥ 1:16 
Antigens: polyvalent CCHFV, RVFV, LASV, 
MARV, EBOV (May), SUDV(Bon): positives 
retested against monovalent antigens 
Areas sampled had no known 
outbreak. Range of titres: 1:16 to 
1:512; highest prevalence in the 
capital Antanarivo 13.3%. 
United States33 1990 
CDC (US) employees with current or 
previous occupational exposure to 
monkeys. None ill. 
 
B 
 
550 
 
42 
EBOV/SUDV/ 
RESTV/MARV 
7.6%  
 IFA (?) ≥ 1:16 
Antigens: EBOV, SUDV, Reston ebolavirus 
(RESTV), MARV. 
Validation: confirmed by western Blot   
 
This paper summarises 2 others 73,74 
Results are for positivity to at least 
one of the four antigens, which 
include Marburg. 
Adult primary care outpatients in US C 449 12 
 
2.7%  
 
Germany34 1991 
Various groups of healthy individuals, 
blood donors and routine diagnostic 
samples, plus 56 individuals who had 
had contact with Marburg patients in 
1972. 
 
C 1288 
 
11  
 
 
44  
EBOV 
0.85% 
 
RESTV 
3.4% 
ELISA  
IFA or  
WB 
ELISA: 1:100 
IFA: 1:40 
 WB: +ve if 
stained ≥ 2 viral 
proteins) 
Antigens: EBOV (May), RESTV, Marv(Mus) 
Validation: Considered positive if ELISA 
confirmed by IFA or WB. 
Confirmation: ELISA vs IFA 75%; ELISA vs 
Western Blot 77%.  
Authors state that the sample groups 
showed no significant differences in 
the prevalence of antibody against 
the 3 filoviruses and so they treated 
as one group for analysis and only 
overall results reported. 
 
WB results: “most” sera reacted with 
the NP protein, “less” with VP40, 
VP35 & VP30, and ‘few’ with VP24.  
None reacted to GP or L proteins. 
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Kikwit, DRC35 1995 
Four forest site populations near 
Kikwit town, site of outbreak 
B 230 5 
EBOV 
2.2% 
ELISA (k) 
≥ 1:400  
&  
OD sum ≥ 1.25 
Antigen: unspecified but Kuhn52 reports EBOV; 
sera tested in CDC (US) Special Pathogens Lab. 
Differentiation between forest and 
city workers was difficult: publicity 
brought people out of their areas: self 
identified occupations. 95%  of 
participants including all 9 positives 
said they  knew someone with Ebola. City workers, Kikwit B 184 4 
EBOV 
2.2% 
Asymptomatic volunteers from 
unaffected villages near Kikwit 
C 161 15 
EBOV 
9.3% 
5/15 positives knew someone who 
had had Ebola 
Kikwit, DRC36 1995 Household contacts aged 3m-58y  A 101 4 
Ebolavirus 
4.0% 
ELISA (k) 
≥ 1:400  
&  
OD sum ≥ 1.25 
Antigen: unspecified but probably EBOV; sera 
tested in CDC (US) Special Pathogens Lab. 
 
Paper cites 5 positive sera but 1 
miscarried 3 days before giving her 
positive specimen so fits case 
definition for Ebola. One of the 
remaining 4 may have acquired Ebola 
by sexual transmission from a 
convalescent. Out of  81 sero-
negative household contacts, 15 had 
episodes of illness fitting case 
definition at some point during 
follow-up. 
 
Central African 
Republic 37 
1992-97 
Pygmy general population: southern 
regions of CAR (Lobaye, Belemboke) 
C 684 48 
EBOV 
7.0% 
ELISA (n)  ≥ 1: 400 
 
Antigens: EBOV, MARV, RVFV, LASV, Yellow 
fever (YF) Hantaviruses (Seoul, Puumala and 
Thottapalayam) 
 
Validation: 244 sera taken in Lobaye in 1995 
(11.6% ELISA positive to EBOV) were retested 
with IFA to EBOV (May) & SUDV (Bon): 34% 
were positive. 
 
Prevalence of EBOV seropositivity 
varied between 2% and 13% in 
different participant groups. 
 Bantu villagers : southern region of 
CAR (Lobaye, Belemboke, Nola, 
Bangassou) 
C 860 44 
EBOV 
5.1% 
Central African 
Republic38 
1992-95 
Pygmy subgroup (Lobaye, Belemboke: 
all sites no known outbreaks) 
 
C 683 48 
EBOV 
7.0% 
ELISA (k) 
Mean + 2 SD of 
negative 
controls ≥1:400 
& OD sum of 4 
dilutions     > 1.0 
Antigens: EBOV (May) Marv(Mus); tests 
performed by Institut Pasteur, Bangui. 
 
Validation: 14 positive & 54 negative samples 
sent to CDC (US) to be tested against strain 
antigens: all results confirmed. 
Primary or secondary forest areas 
with some agricultural activities 
Non-pygmy subgroup (Lobaye, 
Belemboke, Bangassou, Nola: all sites 
no known outbreaks) 
C 648 23 
EBOV 
3.5% 
Ogooue Ivindo, 
Gabon39 
1995-96 
Residents of 3 encampments 
(Andock, Minkebe, Mekoua) in the 
area where the epidemic occurred 
(including some contacts) 
B 236 23 
 
EBOV/SUDV 
/RESTV 
9.7% ELISA (k) 
 
mean + 3 SD of 
negative 
controls 
Antigens: EBOV, SUDV, RESTV with known 
positive/negative controls 
1 positive serum from a survivor 
excluded from encampment group; 
unclear how many known case 
contacts are included in this group. 
Residents of 3 outbreak villages 
(Mayibout 1 & 2, Mvadi) where cases 
were reported during the outbreak 
B 205 34 
 
EBOV/SUDV 
/RESTV 
16.6% 
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Kikwit40 1995 
Healthcare workers in outbreak area 
(70% hospital; 30% health centre) 
who did not have known EVD 
B 400 8 
EBOV 
2.0% 
ELISA (k) 
Sum of adjusted 
OD >1.25 
Antigen: EBOV 
 
The 8 positives were from a group of 
12 samples which were “borderline 
positive” on 1st test. Only 4 of these 
samples were retested: all were 
negative and have been excluded.  
 
129 of the 402 subjects reported 
being ill during Ebola period. Two 
with fever and haemorrhage (tested 
EBOV negative) have been excluded. 
 
Gabon 41 1996 
Selected asymptomatic family 
members directly exposed to body 
fluids during outbreaks in 1996 
 
A 
 
24 
 
11 
EBOV 
45.9% 
ELISA (k) 
Mean adjusted 
OD for 10 
control samples 
Antigen: EBOV 
 
Validation : confirmed with western blot on  
NP and VP40 proteins 
Subjects were asymptomatic 
throughout and were sampled several 
times. 1st samples showed no 
antibodies suggesting no prior 
immunity; IgG appeared 15-18 days 
after first possible exposure.   
Paper also describes results of viral 
RNA detection after 2 rounds of RT-
PCR, finding positive results in 7/11 
antibody-positive individuals tested 
and 0/13 antibody-negative 
individuals. 
Nouna River, Ogooue-
Ivindo, Gabon42 
1996 
Residents in gold-mining villages with 
contact exposure in 1995 epidemic 
A 56 12 
EBOV 
21.4% 
ELISA (?) 
OD > mean +2 
SD of 3 known 
negative 
controls 
Antigen: ebolavirus Gabon 95-39/3 (Centre 
International de Recherches Medicales de 
Franceville) 
All subjects reported fever and 
diarrhoea at least once in 1-year 
period of study, but not haemorrhagic 
symptoms.  IgG positive titre range 
(OD 310-2,666).  
Age, sex, ethnic group not associated 
with seropositivity. Non- significant 
difference in seropositivity in people 
on site during 1995 epidemic (8.2%) 
and not on site (3.7%), among those 
with no reported contact  
Residents in same villages without 
contact exposure 
B 180 12 
EBOV 
6.7% 
Upper Ivindo River, 
Ogooue-Ivindo, 
Gabon43 
 
1997 
Individuals from 8 permanent villages 
in  outbreak-prone region (4 survivors 
excluded)    
B 975 10 
EBOV 
1.0%  
ELISA (k) 
Mean OD 
negative  
controls +3 SD 
Antigen: EBOV, performed in National Institute 
for Communicable Diseases South Africa.   
 
Validation: All positives plus a random 
selection of 28 negatives were retested with 
same protocol in CDC (US) – all were 
confirmed with response mainly directed to 
NP, VP40, VP35 and sGP viral proteins.  
Serosurvey done in 1997; 
questionnaires done in 1999 on 10 
positives: only 1 had contact, none 
were ill.   
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Belarus & Ukraine44 1997 
“Foreign visitors” mostly from Africa: 
unclear if any had history of EVD 
symptoms 
C 562 30 
EBOV 
5.3% 
IFA (w) Not specified 
Antigens: EBOV (May), MARV (Voege) LASV 
(Jos)  
Authors suggest positive results 
among foreign visitors reflect historic 
infection/ recovered cases, and 
unexpected results reflect cross-
reactivity with infections such as 
malaria, HIV and influenza.  Other 
observers suggest the results are just 
as likely to be artifact.63 
Belarus/Ukraine residents “at risk of 
HIV” 
C 506 20 
EBOV 
4.0% 
Blood donors from the Blood 
Transfusion Institute, MoH Belarus & 
workers at the Belorussian Scientific 
Research Institute of Epidemiology & 
Microbiology 
C 131 21 
EBOV 
16.0% 
Watsa region, DRC45 2002 
Efe tribe pygmies exposed to a 
possible case at some time in their 
lives in household, occupation or 
funeral setting; no history of 
haemorrhagic fever symptoms    
A 38 4 
EBOV 
10.5% 
ELISA (k) 
2 × mean +3 SD 
of negative 
controls value 
Antigen: EBOV 
 
ODs were expressed as percent positivity of a 
confirmed EBOV-positive sample; negative 
controls were from 60 South African subjects 
‘almost certain’ to be seronegative.  
 
A total of 300 people were sampled 
from 39 communities. 137 who 
reported experiencing haemorrhagic 
fever symptoms sometime in their life 
are excluded from this summary. 22% 
of those reporting symptoms were 
IgG positive. 
 
Efe pygmies no reported exposure to 
possible cases; no history of 
haemorrhagic fever symptoms    
C 125 22 
EBOV 
17.6% 
Gabon46 2005-08 
Random sample of asymptomatic 
people aged >16 years without 
exposure, over all 9 provinces of 
Gabon 
C 4349 667 
EBOV 
15.3% 
ELISA (k) 
& WB 
Cut-off  based 
on   negative 
controls from a 
French 
population 
Antigen: EBOV 
 
Validation: Random sample of 138 positives 
were tested by western blot in 2008 and all 
were positive to at least one EBOV antigen.53  
Gabon experienced 7 outbreaks 
between 1994 & 2002 affecting >20 
villages and towns; in total there were 
208 cases and 151 deaths. Random sample of asymptomatic 
children from  6 villages in  outbreak-
prone province (Ogooue-Ivindo) 
B 362 47 
EBOV 
12.9% 
Bundibugyo, Uganda47  
 
2007 
Adult contacts of survivors >18 y. 
Samples taken ~29 months after 
outbreak 
A 210 2 
 
EBOV/SUDV/ 
TAFV/BDBV 
1.0% 
ELISA (s) 
Mean OD of 
negative 
controls plus 3 
SD 
 
Antigens: EBOV, SUDV, Tai Forest ebolavirus 
(TAFV), Bundibugyo ebolavirus (BDBV), 
MARV(Mus) 
 
Validation: 28/36 confirmed cases tested 
positive to BDBV, 20/36 to EBOV, 10/36 to 
SUDV, 12/36 to TAFV & 29/39 to any of the 4 
strains. 
 
15/223 contacts positive but 13 were 
symptomatic at the time of the 
outbreak, therefore only the 2 
asymptomatic contacts are included 
in the table. 
Republic of Congo48 2011 
Healthy blood donors 18-65y, no 
known case exposure 
C 809 20 
EBOV 
2.5% 
Double 
IFA 
Reciprocal 
endpoint titres 
≥20 
Antigens: EBOV (ATCC 1978), MARV (Popp 
1967) 
 
Authors state: ‘double IFA’ technique has 
higher specificity than ‘regular’ IFA because 
only antibodies that detect filoviral antigens in 
co-localisation with a monoclonal antibody are 
considered. 
Seropositivity ranged from 1.6% -  4%  
depending on city/rural location; 4% 
in Pointe Noire. 
Liberia [PREVAIL]49 2015 
Close contacts of cases. NB 126 of the 
contacts were sexual partners of 
survivors after  discharge. 
A 760 98 
EBOV 
12.9% 
ELISA 
(Alpha) 
unspecified Antigen: EBOV  
Preliminary results. Study excluded 
from meta-analysis of known case 
contact group (A) because unclear 
what proportion of participants were 
symptomatic. 
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Kono, Sierra Leone50 2015-16 
 
Asymptomatic close contacts of cases 
aged ≥ 4 years who had been resident 
in quarantined houses during the 
period of active Ebola transmission  
A 185s 12 
EBOV 
6.4% 
ELISA 
(Alpha) 
4.7 U/ml 
Antigen: EBOV GP 
 
Validation: 29/30 PCR-confirmed EVD 
survivors, and 3/132 community controls were 
positive: 96.7% sensitivity, 97.7% specificity 
 
2 other positives had fever. Not clear 
if negatives were asked about 
symptoms 
 
 
Individuals from 3 villages without 
reported cases  
C 132 3 2.3 
Western Area, Sierra 
Leone51 
2015 
 
Household contacts of cases, 
asymptomatic at the time EVD was in 
the household 
 
A 388 10 
EBOV 
2.6% ELISA 
(PHE)  
Mean OD of 
negative 
controls + fixed 
OD measure 
(0.1) 
Antigen: EBOV GP.  “Positive” only if repeat 
test was positive 
 
Validation:  93/97 PCR-confirmed EVD 
survivors and 0/339 community controls were 
positive:  sensitivity 95.9% (95%CI 89.9 – 
98.9%); specificity 100% (95%CI 98.9 – 100%) 
Tests were done on oral fluid.   
 
Individuals from 3 villages in Western 
Area without reported EVD cases 
C 339 0 
EBOV 
0% 
 
Abbreviations 
CDC (US): Centers for Disease Control and Prevention, Atlanta, USA; PHE: Public Health England; EBOV: Zaire ebolavirus; SUDV: Sudan ebolavirus; BDBV: Bundibugyo ebolavirus; TAFV: Tai Forest Fever Virus; 
MARV: Marburg Fever Virus; CCHFV: Crimean Congo Haemorrhagic Fever Virus; RVFV: Rift Valley Fever Virus; LASV: Lassa Fever Virus; IFA: immunofluorescence assays; ELISA: Enzyme-linked immunosorbent 
assay; WB: Western Blot; OD: optical density; SD: standard deviation 
 
Assay technique notation 
IFA (w): Wulff & Lange62  
IFA( j): Johnson63 
IFA (g): Gardner64 
IFA (b) Baskirtsev65  
Double IFA: Emmerich66 
IFA (?) ELISA (?): technique not referenced 
ELISA (k): Ksiazek67 
ELISA (s): Schoepp68 
ELISA (v): Viral Haemorrhagic Fever Consortium (SL)69  
ELISA (n): Nicklasson70  
ELISA(r) : Rezapkin71 
ELISA(PHE): Lambe54   
ELISA(Alpha): ADI75  
 
